Raising the bar

The curative potential of human cancer immunotherapy

Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

Original languageEnglish (US)
Article number127ps8
JournalScience Translational Medicine
Volume4
Issue number127
DOIs
StatePublished - Mar 28 2012
Externally publishedYes

Fingerprint

Adoptive Transfer
Immunotherapy
Melanoma
Antigen Receptors, T-Cell, alpha-beta
Antigen Receptors
Genetic Engineering
Kidney Neoplasms
Interleukin-2
Neoplasms
T-Lymphocytes
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raising the bar : The curative potential of human cancer immunotherapy. / Rosenberg, Steven A.

In: Science Translational Medicine, Vol. 4, No. 127, 127ps8, 28.03.2012.

Research output: Contribution to journalArticle

@article{bd2a1c42f208453abd603d8caaf69740,
title = "Raising the bar: The curative potential of human cancer immunotherapy",
abstract = "Immunotherapy with interleukin-2 can cure 5 to 10{\%} of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40{\%}. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.",
author = "Rosenberg, {Steven A.}",
year = "2012",
month = "3",
day = "28",
doi = "10.1126/scitranslmed.3003634",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "127",

}

TY - JOUR

T1 - Raising the bar

T2 - The curative potential of human cancer immunotherapy

AU - Rosenberg, Steven A.

PY - 2012/3/28

Y1 - 2012/3/28

N2 - Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

AB - Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

UR - http://www.scopus.com/inward/record.url?scp=84859153479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859153479&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003634

DO - 10.1126/scitranslmed.3003634

M3 - Article

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 127

M1 - 127ps8

ER -